EXHIBIT 99.1

WaferGen Bio-systems Reports Results for Third Quarter 2015

Company Reports Record Quarterly Revenues of $2.0 Million

Commercial Launch of ICELL8™ Single Cell System Expected to Drive Further Revenue Growth

Successful Completion of $17.25 Million Offering Supports ICELL8™ Commercialization

FREMONT, California -- November 10, 2015
WaferGen Bio-systems, Inc. (NasdaqCM: WGBS) announced today its financial results for the third quarter and nine months ended September 30, 2015.

Key Recent Highlights

Commercially launched the ICELL8™ Single Cell System at the American Society of Human Genetics annual meeting

Successfully completed a public offering of WaferGen securities that raised gross proceeds of $17.25 million to support research and development and commercialization activities for our single cell products, as well as for sales and marketing activities and for general corporate and working capital purposes

Presented results from the ICELL8™ Single Cell System at the Single Cell Genomics Conference in Utrecht, The Netherlands, that included work from early access collaborators at The University of Texas MD Anderson Cancer Center

Obtained from the U.S. Patent and Trademark Office a patent and a notice of allowance for a patent application, each with method and system claims utilizing multi-well chips, providing greater strength for WaferGen’s core SmartChip™ products and applications, including the ICELL8 Single Cell System

Signed a supply agreement with Reprogenetics for use of WaferGen’s Apollo 324™ Next Generation Sequencing (NGS) sample preparation system to enable automation of NGS library preparation for Preimplantation Genetic Screening testing used in in vitro fertilization

SmartChip platform selected by Annoroad for high-throughput target enrichment of BRCA1 and BRCA2 genes, SNP genotyping services and library quantification for NGS

“Over the past few months, our business has gained significant momentum,” said Rollie Carlson, Ph.D., President and Chief Executive Officer of WaferGen. “With our base business performing strongly following two quarters of sequential revenue growth, and the recent commercial launch of our revolutionary ICELL8 Single Cell System, WaferGen is well positioned for long-term success. In addition, following our recent public securities offering, the Company is now well capitalized in order to support a number of key corporate initiatives, including ICELL8-related commercialization activities.”



The following information was filed by Wafergen Biosystems, Inc. (WGBS) on Tuesday, November 10, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Wafergen Biosystems, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Wafergen Biosystems, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account